newsletter subscription
email
Satellite Symposia
Satellite Symposium 1
Krystal Biotech - Platinum Partner
Tuesday, 28 April 2026
16:00 - 17:00, Sala Mantegna
Dystrophic Epidermolysis Bullosa: current understanding, evolving management, and clinical practice insights
Symposium Flyer
16:00–16:05
Welcome and Introduction
May El-Hachem, Dermatology Unit, Genodermatosis Research Unit, Translational Paediatrics and Clinical Genetics Research Area, Bambino Gesù Children’s Hospital, Rome, Italy.
16:05–16:15
DEB Today: wound complications and need for early management
May El-Hachem, Dermatology Unit, Genodermatosis Research Unit, Translational Paediatrics and Clinical Genetics Research Area, Bambino Gesù Children’s Hospital, Rome, Italy
16:15–16:35
From palliative care to corrective therapies: the evolving DEB treatment landscape
Peter Marinkovich, Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
16:35–16:50
Lessons from the clinic: real‑world outcomes and optimization strategies in DEB care
Ayşe Öktem, Department of Dermatology, Ankara University Faculty of Medicine, Ankara, Turkey
16:50–17:00
Conclusion and Q&A
Satellite Symposium 2
Viatris - Platinum Partner
Tuesday, 28 April 2026
16:00 - 17:00, Mantegna Media 1
The Evolving Landscape of Atopic Dermatitis (AD)
16:00 – 16:02
Welcome and objectives
Dra. Ángela Hernández Martín, Spain
Dra. Ángela Hernández Martín, Spain
16:02 – 16:17
The Role of the Skin Barrier in AD and the Atopic March
The Role of the Skin Barrier in AD and the Atopic March
Prof. Beatrix Volc-Platzer, Austria
16:17 – 16:32
Treating AD infants and children: do we need different approaches?
Treating AD infants and children: do we need different approaches?
Prof. Ulrich Wahn, Germany
16:32 – 16:47
Advances in targeted systemic therapies in AD
Advances in targeted systemic therapies in AD
Dra. Ángela Hernández Martín, Spain
16:47 – 16:50
Key takeaways
Prof. Beatrix Volc- Platzer, Austria
Key takeaways
Prof. Beatrix Volc- Platzer, Austria
16:50 – 17:00
Q and A
All
Q and A
All
Satellite Symposium 3
Pfizer - Diamond Partner
Wednesday, 29 April 2026
12:40 - 13:40, Sala Mantegna
Title: Ask the Experts: Practical Approaches for Alopecia Areata and Atopic Dermatitis Management in Adolescents
Objectives:
- Highlight the unique burden for adolescent patients with alopecia areata (AA) and atopic dermatitis (AD) and the importance of prompt, appropriate treatment
- Review the data for ritlecitinib and abrocitinib in adolescent patients with AA and AD
- Discuss best practices for navigating management challenges of AA and AD through patient case studies
Speakers:
Antonio Torrelo, MD, Madrid, Spain
Michela Starace, MD, PhD, Bologna, Italy
Satellite Symposium 4
Unifarco - Gold Partner
Wednesday, 29 April 2026
16:25 - 17:25, Sala Mantegna
Title: “Targeted Cleansing Strategies for Atopic Dermatitis in Children: Hard Water Impact on Skin Barrier Structure and Function”
16.25-16.30
Welcome and Introduction:
Prof. Andrea Peserico
President Emeritus of the Italian Society of Dermatology , Italy
16.30-16.50
Pediatric Atopic Dermatitis: From Skin Barrier Dysfunction to Skin Care Management
Prof. Domenico Bonamonte
Head of Pediatric Dermatology and Rare Skin Diseases, University of Bari, Italy
16.50-17.15
Hard Water and Skin Barrier: New Approaches to Targeted Cleansing
Marisa Meloni, PhD, PharmaD, In Vitro Science and NAMs Expert, Italy
17.15-17.25
Q&A
All Speakers
Satellite Symposium 5
Chiesi - Bronze Partner
Thursday, 30 April 2026
10:45 - 11:45, Sala Mantegna
Title: Oleogel S-10: Redefining the Standards of Care in Patients with Epidermolysis Bullosa (DEB and JEB)
Speakers:
Prof. Andrea Diociaiuti
Prof. Giuseppe Micali
Moderator:
Anna Belloni Fortina
Satellite Symposium 6
Galderma - Bronze Partner
Thursday, 30 April 2026
10:45 - 11:45, Mantegna Media 1
Title: IL-31: is it itch management only?
Chairman: Prof. A. Belloni Fortina
the IL-31 pathways
Prof. S. Garcovich
Prof. S. Garcovich
Nemolizumab in adolescent patients with AD: Phase III trials results
Prof. A. Belloni Fortina
Prof. A. Belloni Fortina
Abstract:
IL-31 is well recognized as the “itch cytokine” but its role is much broader. It is involved in type 2 inflammation, epidermal dysregulation and fibrosis.
Blocking IL-31 receptor is crucial in inhibiting all these pathways and it can provide significant clinical results.
In the Phase III pivotal trials, even adolescent patients affected by AD were recruited. The results obtained in this subpopulation of patients will be discussed.
ESPD OFFICE
domain
Address for official postal correspondence:
ESPD Office
c/o C-IN
5. kvetna 65, Prague Congress Centre
140 21 Prague 4
Czech Republic
Registered at:
1 Place de l'Hôpital
670 91 Strasbourg CEDEX
France
mail_outline
Office email address
office@espd.info
Copyright © 2022 European Society for Pediatric Dermatology
Powered by APPTIDE | Created by C-IN | Privacy Policy